Work

Once-daily indacaterol/glycopyrronium reduces the rate and risk of moderate or severe exacerbations compared with twice-daily salmeterol/fluticasone in a subset of gold froup D COPD patients with a history of >= 2 exacerbations or 1 hospitalization: the FLAME study

Year: 2018

Type: article

Source: Pneumologie

DOI: 10.1055/s-0037-1619355

Authors: C Vogelmeier, J Wedzicha, J Donohue, S Fucile, A Yadao, T Ayers, C Thach, A FowlerTaylor, R Fogel, F Patalano, D Banerji

Institutions: Philipps University of Marburg, Universitätsklinikum Gießen und Marburg, German Center for Lung Research, Imperial College London, Novartis (Switzerland)

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2791853267

FWCI:

Cites:

Cited by:

Related to: 10